Early Chemotherapy

Choosing Docetaxel or Zytiga

Both Taxotere (docetaxel) and Zytiga (abiraterone) are approved for newly diagnosed men with very aggressive prostate cancer and who have not yet had any exposure to hormone therapy (ADT).  

The two approvals lead us to the question, which of these treatment options would be best for you? 

Confirming The Value of Early Docetaxel in Men With Metastatic Hormone-Sensitive Prostate Cancer

Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT. 

A Real-World Analysis Of Outcomes of Early Chemotherapy in Men Newly Diagnosed With Metastatic Prostate Cancer

Recent research has concluded that for men who are going to use early chemotherapy along with hormone therapy, chemotherapy should be delayed, allowing at least three weeks to pass after starting the hormone therapy before commencing the chemotherapy treatments.